Unity Biotechnology, Inc. Deferred Tax Assets, Valuation Allowance
Unity Biotechnology, Inc. had Deferred Tax Assets, Valuation Allowance of $117.85 million as of 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2025-03-07
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $117.85M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $109.71M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $100.35M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $86.90M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2024-12-31 | $117.85M 10-K · filed 2025-03-07 |
| 2023-12-31 | $109.71M 10-K · filed 2025-03-07 |
| 2022-12-31 | $100.35M 10-K · filed 2024-04-15 |
| 2021-12-31 | $86.90M 10-K · filed 2023-03-15 |
| 2020-12-31 | $70.95M 10-K · filed 2022-03-15 |
| 2019-12-31 | $48.83M 10-K · filed 2021-03-23 |
| 2018-12-31 | $37.88M 10-K · filed 2020-03-11 |
| 2017-12-31 | $20.24M 10-K · filed 2019-03-06 |